Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin D. Bunker on December 23, 2014 and is headquartered in New York, NY.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

The average of price targets set by Wall Street analysts indicates a potential upside of 170.4% in Zentalis Pharmaceuticals, Inc. (ZNTL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Can Zentalis Pharmaceuticals, Inc. (ZNTL) Climb 170% to Reach the Level Wall Street Analysts Expect?

Six sponsored studies with potentially first-in-class Wee1 inhibitor, ZN-c3, ongoing and continuing dose optimization work, as drug continues to show improved tolerability in initial safety data from monotherapy Phase 2 USC trial announced today

Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates

NEW YORK and SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Kimberly Blackwell, MD, Chief Executive Officer of Zentalis, will participate in a fireside chat at the Stifel 2022 Healthcare Conference on Tuesday, November 15, 2022 at 1:15 p.m. ET.

Zentalis Pharmaceuticals to Participate in the Stifel 2022 Healthcare Conference

Companies will collaborate on Phase 1/2 dose escalation study of ZN-c3, a selective Wee1 inhibitor, in combination with encorafenib and cetuximab in patients with BRAF V600E-mutated colorectal cancer Companies will collaborate on Phase 1/2 dose escalation study of ZN-c3, a selective Wee1 inhibitor, in combination with encorafenib and cetuximab in patients with BRAF V600E-mutated colorectal cancer

Zentalis Pharmaceuticals Announces First ZN-c3 Clinical Development Collaboration with Pfizer

NEW YORK and SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Mark Lackner, PhD, as Chief Translational Officer, Head of Biomarker Strategy. Dr. Lackner, an esteemed cancer biologist, joins Zentalis with over two decades of oncology-focused drug development expertise, including significant experience in biomarker discovery and clinical biomarker strategies.

Zentalis Pharmaceuticals Appoints Dr. Mark Lackner as Chief Translational Officer, Head of Biomarker Strategy

NEW YORK and SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the promotion of co-founder Kevin Bunker, Ph.D., to Chief Scientific Officer. In this new role, Dr. Bunker will focus on leading Research and Development (R&D) in San Diego, advancing the preclinical pipeline and optimizing the Company's Integrated Discovery Engine.

Zentalis Pharmaceuticals Promotes Co-Founder Kevin Bunker, Ph.D. to Chief Scientific Officer

NEW YORK and SAN DIEGO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Carrie Brownstein, MD, as Chief Medical Officer (CMO), effective October 3, 2022. Dr. Brownstein, a leading oncologist and hematologist by training, joins Zentalis with over two decades of medical and biopharmaceutical experience executing clinical program strategies across all phases of product development.

Zentalis Pharmaceuticals Appoints Dr. Carrie Brownstein as Chief Medical Officer

NEW YORK and SAN DIEGO, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Jan Skvarka, PhD, MBA to its Board of Directors. Dr. Skvarka is an accomplished biopharmaceutical executive bringing over three decades of extensive operational, strategic and financial expertise to Zentalis.

Zentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directors

Zentalis Pharmaceuticals, Inc. (ZNTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zentalis Pharmaceuticals, Inc. (ZNTL) Upgraded to Buy: Here's What You Should Know

The consensus price target hints at a 128.7% upside potential for Zentalis Pharmaceuticals, Inc. (ZNTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Zentalis Pharmaceuticals, Inc. (ZNTL) Have the Potential to Rally 129% as Wall Street Analysts Expect?

Zentalis Pharmaceuticals (ZNTL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Zentalis Pharmaceuticals (ZNTL) Might Surprise This Earnings Season

Strengthened leadership team with the appointment of additional industry veterans, including CEO Dr. Kimberly Blackwell and Chairman Dave Johnson

Zentalis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update

NEW YORK and SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Kimberly Blackwell, MD, Chief Executive Officer of Zentalis, will participate in a panel discussion entitled “Bullseye – Targeted Oncology – Quanta of Targets” at the Wedbush PacGrow Healthcare Conference on Wednesday, August 10, 2022 at 10:20 a.m. ET.

Zentalis Pharmaceuticals to Participate in the Wedbush PacGrow Healthcare Conference

NEW YORK and SAN DIEGO, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on August 1, 2022, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 290,500 shares of its common stock to Andrea Paul, who joined Zentalis as its General Counsel and Corporate Secretary. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (the “2022 Inducement Plan”) as an inducement material to Ms. Paul's entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).

Zentalis Pharmaceuticals, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and SAN DIEGO, June 27, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Andrea Paul, J.D., as General Counsel and Corporate Secretary, effective August 1, 2022. Ms. Paul brings several years of legal leadership experience in the healthcare industry to Zentalis.

Zentalis Pharmaceuticals Appoints Andrea Paul as General Counsel and Corporate Secretary

NEW YORK and SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the promotion of Cofounder Cam Gallagher, MBA, to President. Mr. Gallagher, who previously served as an Executive Director of Zentalis, will remain a member of the Board of Directors, which he has served on since the Company's founding. He will report to Chief Executive Officer Dr. Kimberly Blackwell.

Zentalis Pharmaceuticals Promotes Cofounder Cam Gallagher to President

NEW YORK and SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the closing of an underwritten offering of 10,330,000 shares of its common stock at an offering price of $19.38 per share, for total gross proceeds of approximately $200.2 million, before deducting underwriting discounts and commissions and offering expenses payable by Zentalis. All of the common stock was offered by Zentalis. Zentalis intends to use the net proceeds of the offering to help fund ongoing and planned clinical trials, including the clinical development of ZN-c3 and ZN-d5, and for working capital and other general corporate purposes.

Zentalis Pharmaceuticals Announces Closing of Underwritten Offering of Common Stock

Announced initial data on ZN-c3 in combination with chemotherapy in advanced ovarian cancer and interim data on ZN-c3 in uterine serous carcinoma (USC) at AACR

Zentalis Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update

Pfizer

Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) will sell 953,834 common shares at $26.21 per share to Pfizer Inc (NYSE: PFE) for $25 million.  The offering is expected to close by April 29.

Pfizer Injects $25M Via Equity In Zentalis Pharma

Zentalis and Pfizer plan to jointly advance the clinical development of ZN-c3, a selective Wee1 inhibitor designed to induce synthetic lethality in cancer cells

Zentalis Pharmaceuticals Announces $25 Million Equity Investment from Pfizer

The heavy selling pressure might have exhausted for Zentalis Pharmaceuticals, Inc. (ZNTL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Here's Why Zentalis Pharmaceuticals, Inc. (ZNTL) is Poised for a Turnaround After Losing 50% in 4 Weeks

ZN-c3 in combination with chemotherapy demonstrated strong anti-tumor activity in a heavily pretreated population, with an ORR of 30.2% across all evaluable chemotherapy cohorts

Zentalis Pharmaceuticals Announces Overview of Clinical and Preclinical Data Presented at AACR

Zentalis Pharmaceuticals Announces Positive Initial Clinical Data on ZN-c3, its Wee1 Inhibitor, in Patients with Advanced Ovarian Cancer at AACR

NEW YORK and SAN DIEGO, March 09, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will present a corporate presentation at the Oppenheimer Annual Healthcare Conference on Wednesday, March 16, 2022 at 10:00 a.m. ET.

Zentalis Pharmaceuticals to Present at the Oppenheimer Annual Healthcare Conference

Updated data from Phase 1 expansion cohort of ZN-c3 in uterine serous carcinoma (USC) will be presented during a mini symposium session Updated data from Phase 1 expansion cohort of ZN-c3 in uterine serous carcinoma (USC) will be presented during a mini symposium session

News for Zentalis Pharmaceuticals Stock (ZNTL)